In fact, our ongoing work further indicates that the Sp1-BCL9-2 interaction drives the expression of additional target genes in cancer cells and that this interaction does not require the ß-catenin binding domain of BCL9-2 (Wiese and Brembeck, manuscript in preparation). Here, BCL9L is linked to cancer.